

Terms of reference and conditions

1	Customer:	State Health Insurance Fund
2	Contents of selection	Selection of the best proposals for determining the marginal cost of reimbursement of medicines (in terms of the form of release, dose, and international nonproprietary name (INN) provided based on the reimbursement program
3	Selection type	Selecting the best offer
4	Source for downloading the selection documentation	https://dtsj.uz/uz/reimbursatsiya/
5	Documents submitted for participation in the selection	 Provision of a certificate of conformity for each medicinal product according to INN, trade name, form of release and dosage (Appendix #1) Submission of a competitive price offer for each medicinal product according to INN, trade name, form of release, and dosage (Appendix #2). In this case, the competitive price offer should not exceed the reference price for this medicinal product according to INN, trade name, and dosage. Provision of a letter of guarantee on prevention of corruption risks.
6	Time and address of receiving bids	Competitive price offers are provided by e-mail (<u>reimbursement@dtsj.uz</u>) within 10 (ten) business days from the date this announcement is posted for each medicinal product in the context of INN, trade name, form of release, and dosage.
7	The procedure and deadline for evaluating bids	 Competitive price proposals will be reviewed within 5 (five) business days after the deadline for submitting competitive proposals at a meeting of the Commission formed under the State Health Insurance Fund. Based on competitive price proposals, a list of prices is formed in ascending order by INN, trade names, forms of release, and dosages. Then, starting from the lowest price

index, 5 (five) medicines are selected by trade name, form of release, and dosage.

3. Based on the proposed price, the maximum cost of reimbursement is set for the trade name, form, and dose of the selected medicines. At the same time, the proposed price, retail trade allowance, and VAT are taken into account as part of the marginal cost of reimbursement.

4. The highest marginal cost of reimbursement among the selected medicines is taken as the highest marginal cost of reimbursement for INN, form, and dose of this medicinal product.

5. Suppliers who have submitted their proposals to the State Medical Insurance Fund are notified of the accepted marginal cost of reimbursement for INN, form, and dose of the corresponding drug through the State Health Insurance Fund's website (https://dtsj.uz/ru/reimbursatsiya).

Suppliers who have offered prices exceeding the maximum cost of compensation are allowed to change the prices indicated in their offer to prices not exceeding the maximum cost of compensation, and within 48 hours to submit updated offers by the established procedure to the e-mail of the State Medical Insurance Fund. (reimbursement@dtsj.uz).

6. The Commission shall consider the updated proposals within 2 (two) working days and, together with the preliminary meeting results, approve the list of medicines with an appropriate protocol indicating the trade name, form, and dose of medicines and the marginal cost of reimbursement for each INN, form, and dose of medicines.
7. The minutes of the Commission's meeting and the approved list of trade names, forms, and dosages of medicines, as well as the maximum cost of reimbursement, are published on the website of the State Health Insurance Fund (https://dtsj.uz/ru/reimbursatsiya /) and social media pages on the next business day after signing this protocol.

List of medicines provided based on the reimbursement program by dosage form and volume

T/p	International nonproprietary name	Dosage form	Volume (pcs.)
	I. Drugs used to treat pathologies	s of the gastrointestinal tract Proton Pur	np Inhibitors
1.4		roton Pump Inhibitors	
1	Omeprazole	10 mg capsule	494231
	Omeprazole	10 mg capsule	4971286
	Omeprazole	10 mg capsule	1662530
		H2 blockers	
	II. Drugs that af	ffect peripheral adrenergic processes	
		atic and chronic obstructive pulmonary d	isease
2	Salbutamol	aerosol 100 mcg/dose 7 g 200 dose	675355
		reat pathologies of the endocrine system	
	9	Iodine preparations	
3	Potassium iodide	200 mcg tablet	6258827
		Antithyroid drugs	
4	Thiamazole	5 mg tablet	159869
44.0		Thyroid hormones	
5	Levothyroxine sodium	tablet of 100 mcg	443613
	*	Thyroid hormones	•
-	Desmopressin 100 mcg	nasal drops 100 mcg/ml 5 ml	162875
6		metered nasal spray 10 mcg/ dose 5 ml	71016
1		Expectorant agents	
7	Ambroxol	30 mg tablet	1650797
	Medicines tha	at affect the cardiovascular system	
		Antiarrhythmic drugs	
8	Verapamil	tablet 80 mg	158756
	rr	Antianginal drugs	
		spray 1.25 mcg/dose 15 ml 300 dose	39272
9	Isosorbide dinitrate	tablet 10 mg	501893
	Isosorbite mononitrate	20 mg tablet	265881
	Isosorbite mononitrate	40 mg tablet	261115
10	Isosorbite mononitrate	capsule 20 mg	240357
	Isosorbite mononitrate	capsule 40 mg	228554
		Antiplatelet agents	
	Acetylsalicylic acid	tablet 50 mg	391747
	Acetylsalicylic acid	tablet 75 mg	392213
11	Acetylsalicylic acid	tablet 100 mg	912040
	Acetylsalicylic acid	tablet 150 mg	511133
12	Clopidogrel	tablet 75 mg	5552213
		rdioselective) β1–adrenoblockers	
	Bisoprolol	tablet 2,5 mg	783507
13	Bisoprolol	tablet 5 mg	3815619
	Bisoprolol	tablet 10 mg	1365107
	*	cium Channel Blockers	
		tablet 5 mg	4398508
14	Amlodipine		1270200

		in converting enzyme inhibitors	
15	Enalapril maleat	tablet 5 mg	8939816
	Enalapril maleat	tablet 10 mg	12661204
		Hypolipidemic agents	
16	Atorvastatin	tablet 10 mg	3441903
	Atorvastatin	tablet 20 mg	5102783
	Atorvastatin	tablet 40 mg	1516689
	Atorvastatin	tablet 80 mg	945818
	Agents that affect	platelet aggregation and blood clo	~ ~ ~
	Warfarin	tablet 2,5 mg	6095587
17	Warfarin	tablet 3 mg	6087808
	Warfarin	tablet 5 mg	546490
		etic and antidiuretic agents	
	Spironolactone	tablet 2,5 mg	1699006
18	Spironolactone	tablet 50 mg	1527704
in and	Spironolactone	tablet 100 mg	838664
19	Furosemide	tablet 40 mg	1586081
	Drugs used to tre	eat pathologies of the endocrine sys	tem
		Anti-diabetes drugs	
20	Gliclazide	tablet 30 mg	3951809
20	Gliclazide	tablet 60 mg	3826385
	Metformin	tablet 500 mg	9403927
21	Metformin	tablet 850 mg	6764612
	Metformin	tablet 1000 mg	5964768
22	Empagliflozin	tablet 10 mg	1448111
22	Empagliflozin	tablet 25 mg	1359987
	Hormones of the barl	x part of the adrenal gland, glucoco	
23	Prednisone	tablet 5 mg	1151701
	IX. Vi	tamins and their derivatives	
24	Folic acid	tablet 1 mg	1431055
24	Folic acid	tablet 5 mg	1243595
	Drugs	hat stimulate erythropoiesis	
25	Preparations of divalent Fe (II)	tablet 100 mg	3456197
25	Preparations of divalent Fe (II)	capsule 100 mg	2787188
26	Trivalent Fe (III) preparation	tablet 100 mg	4717591
26	Trivalent Fe (III) preparation	capsule 100 mg	4390200
	· / • •	Anthelmintic agents	
27	Albendazole	tablet	1763153
27	Albendazole	capsule	281676

APPENDIX #2

Submission of competitive proposals

#	INN	Trade name	Dosage	Price
1				
2				
	and compared to			

Note: Name of the organization ______ Full name of the supervisor seal (signature)

The proposals must be signed and scanned (PDF file) and submitted with an Excel file